vs
CSW INDUSTRIALS, INC.（CSW）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是再鼎医药的1.8倍（$233.0M vs $127.1M），CSW INDUSTRIALS, INC.同比增速更快（20.3% vs 17.1%），CSW INDUSTRIALS, INC.自由现金流更多（$22.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.1%）
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CSW vs ZLAB — 直观对比
营收规模更大
CSW
是对方的1.8倍
$127.1M
营收增速更快
CSW
高出3.2%
17.1%
自由现金流更多
CSW
多$49.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $233.0M | $127.1M |
| 净利润 | $10.3M | — |
| 毛利率 | 39.7% | 51.0% |
| 营业利润率 | 7.4% | -54.6% |
| 净利率 | 4.4% | — |
| 营收同比 | 20.3% | 17.1% |
| 净利润同比 | -61.9% | — |
| 每股收益（稀释后） | $0.62 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSWZLAB
| Q4 25 | $233.0M | $127.1M | ||
| Q3 25 | $277.0M | $115.4M | ||
| Q2 25 | $263.6M | $109.1M | ||
| Q1 25 | $230.5M | $105.7M | ||
| Q4 24 | $193.6M | $108.5M | ||
| Q3 24 | $227.9M | $101.8M | ||
| Q2 24 | $226.2M | $100.1M | ||
| Q1 24 | $210.9M | $87.1M |
净利润CSWZLAB
| Q4 25 | $10.3M | — | ||
| Q3 25 | $40.7M | $-36.0M | ||
| Q2 25 | $40.9M | $-40.7M | ||
| Q1 25 | $35.1M | $-48.4M | ||
| Q4 24 | $26.9M | — | ||
| Q3 24 | $36.1M | $-41.7M | ||
| Q2 24 | $38.6M | $-80.3M | ||
| Q1 24 | $31.8M | $-53.5M |
毛利率CSWZLAB
| Q4 25 | 39.7% | 51.0% | ||
| Q3 25 | 43.0% | 59.5% | ||
| Q2 25 | 43.8% | 60.6% | ||
| Q1 25 | 44.2% | 63.6% | ||
| Q4 24 | 41.4% | 61.5% | ||
| Q3 24 | 45.6% | 64.1% | ||
| Q2 24 | 47.5% | 64.9% | ||
| Q1 24 | 44.4% | 61.4% |
营业利润率CSWZLAB
| Q4 25 | 7.4% | -54.6% | ||
| Q3 25 | 20.5% | -42.3% | ||
| Q2 25 | 20.8% | -50.3% | ||
| Q1 25 | 19.5% | -53.3% | ||
| Q4 24 | 15.3% | -62.6% | ||
| Q3 24 | 22.6% | -66.6% | ||
| Q2 24 | 24.3% | -76.0% | ||
| Q1 24 | 21.0% | -80.7% |
净利率CSWZLAB
| Q4 25 | 4.4% | — | ||
| Q3 25 | 14.7% | -31.2% | ||
| Q2 25 | 15.5% | -37.3% | ||
| Q1 25 | 15.2% | -45.8% | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 15.8% | -40.9% | ||
| Q2 24 | 17.1% | -80.2% | ||
| Q1 24 | 15.1% | -61.4% |
每股收益（稀释后）CSWZLAB
| Q4 25 | $0.62 | $-0.05 | ||
| Q3 25 | $2.41 | $-0.03 | ||
| Q2 25 | $2.43 | $-0.04 | ||
| Q1 25 | $2.05 | $-0.04 | ||
| Q4 24 | $1.60 | $-0.09 | ||
| Q3 24 | $2.26 | $-0.04 | ||
| Q2 24 | $2.47 | $-0.08 | ||
| Q1 24 | $2.03 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $715.5M |
| 总资产 | $2.3B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSWZLAB
| Q4 25 | $40.2M | $689.6M | ||
| Q3 25 | $31.5M | $717.2M | ||
| Q2 25 | $38.0M | $732.2M | ||
| Q1 25 | $225.8M | $757.3M | ||
| Q4 24 | $213.8M | $779.7M | ||
| Q3 24 | $273.2M | $616.1M | ||
| Q2 24 | $18.9M | $630.0M | ||
| Q1 24 | $22.2M | $650.8M |
总债务CSWZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
股东权益CSWZLAB
| Q4 25 | $1.1B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.0B | $840.9M | ||
| Q3 24 | $1.0B | $667.7M | ||
| Q2 24 | $650.2M | $704.2M | ||
| Q1 24 | $615.7M | $762.2M |
总资产CSWZLAB
| Q4 25 | $2.3B | $1.2B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.4B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.4B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.0B | $988.4M |
负债/权益比CSWZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $22.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 9.8% | -21.0% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.81× | — |
| 过去12个月自由现金流最近4个季度 | $162.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CSWZLAB
| Q4 25 | $28.9M | $-26.0M | ||
| Q3 25 | $61.8M | $-32.0M | ||
| Q2 25 | $60.6M | $-31.0M | ||
| Q1 25 | $27.3M | $-61.7M | ||
| Q4 24 | $11.6M | $-55.8M | ||
| Q3 24 | $66.8M | $-26.8M | ||
| Q2 24 | $62.7M | $-42.2M | ||
| Q1 24 | $22.4M | $-90.1M |
自由现金流CSWZLAB
| Q4 25 | $22.7M | $-26.7M | ||
| Q3 25 | $58.7M | $-35.0M | ||
| Q2 25 | $57.7M | $-33.9M | ||
| Q1 25 | $22.8M | $-63.2M | ||
| Q4 24 | $8.5M | $-58.4M | ||
| Q3 24 | $61.3M | $-28.2M | ||
| Q2 24 | $59.6M | $-42.9M | ||
| Q1 24 | $17.5M | $-91.1M |
自由现金流率CSWZLAB
| Q4 25 | 9.8% | -21.0% | ||
| Q3 25 | 21.2% | -30.4% | ||
| Q2 25 | 21.9% | -31.1% | ||
| Q1 25 | 9.9% | -59.9% | ||
| Q4 24 | 4.4% | -53.8% | ||
| Q3 24 | 26.9% | -27.7% | ||
| Q2 24 | 26.3% | -42.9% | ||
| Q1 24 | 8.3% | -104.5% |
资本支出强度CSWZLAB
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 1.6% | 2.4% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 1.4% | 0.7% | ||
| Q1 24 | 2.3% | 1.1% |
现金转化率CSWZLAB
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
